Information Provided By: 
Fly News Breaks for February 28, 2019
IONS
Feb 28, 2019 | 05:32 EDT
Piper Jaffray analyst Tyler Van Buren raised his price target for Ionis Pharmaceuticals to $60 citing a good first quarter for Tegsedi. While early, the $2.2M in sales reported for Tegsedi in the first partial quarter was a surprise to many, compares well to the $0.5M reported in the first Onpattro quarter, and caused the shares to be up significantly yesterday, Van Buren tells investors in a research note. The analyst, however, keeps a Neutral rating on Ionis due to valuation.
News For IONS From the Last 2 Days
There are no results for your query IONS
